Show MeYes, a baby can be born with HSV-1, but this is uncommon and almost always reflects infection around birth rather than infection inside the womb. The virus is usually acquired during delivery when genital or oral HSV-1 is shed, or after birth from a caregiver with a cold sore. True congenital HSV-1 from transplacental passage is rare. Neonatal HSV affects about 1 in 2,500 to 1 in 10,000 live births in the United States, per CDC 2024 estimates, and HSV-1 causes a substantial share. Without early IV acyclovir, disseminated disease can be fatal; with treatment, outcomes improve substantially.
How a Newborn Acquires HSV-1
HSV-1 is a neurotropic DNA virus that infects mucosal surfaces and skin. In a newborn, the virus enters through the conjunctiva, mouth, or small skin breaks during passage through the birth canal. It can also ascend after membrane rupture or arrive after birth from oral secretions. The virus first replicates in epithelial cells, then spreads to sensory neurons and, in severe cases, to the liver, lungs, adrenal glands, and central nervous system. The neonatal immune system is less able to contain this first infection than an adult immune system is.
The most important mechanism is maternal genital shedding at delivery. A primary genital HSV-1 infection near term is especially dangerous because the mother has not yet transferred protective antibody. IgG crosses the placenta mainly after 32 to 36 weeks, so a primary infection in the last weeks of pregnancy leaves the infant with little neutralizing antibody. A recurrent infection still carries risk, but far less, because maternal antibody and lower viral shedding reduce transmission.
Perinatal transmission accounts for most neonatal HSV. Postnatal transmission from a cold sore, hand lesion, or breast lesion is less common but preventable. True intrauterine infection is rare and can cause skin vesicles, chorioretinitis, microcephaly, or hydranencephaly at birth. Clinicians often call all infant infections “neonatal HSV,” but the timing matters for prognosis and treatment.
Risk rises with prolonged membrane rupture, especially beyond 6 hours, and with fetal scalp electrodes or other invasive monitoring. Prematurity adds risk because the skin barrier is thinner and maternal antibody transfer is lower. Cesarean delivery reduces risk when performed before labor and membrane rupture, but it does not eliminate risk after membranes have been ruptured for hours. In plain terms: most newborns are exposed at delivery, not infected in the womb.
Can You Be Born With HSV-1? Timeline of Exposure and Symptoms
Can You Be Born With HSV-1? Timeline of Exposure and Symptoms
The phrase “born with HSV-1” can mean two different things. A newborn may be infected before birth, which is true congenital infection, or may be infected during birth and develop symptoms days later. The second pattern is far more common. Most neonatal HSV becomes visible between days 5 and 14 of life, but the range extends from the first 24 hours to 6 weeks.
| Phase | Typical timing | What happens |
|---|---|---|
| Maternal shedding | Last 7 to 14 days before delivery | Genital HSV-1 may shed with or without visible lesions |
| Delivery exposure | Minutes to hours | Virus contacts conjunctiva, mouth, or skin |
| Incubation | 2 to 14 days typical; rare to 6 weeks | Virus replicates before symptoms appear |
| Skin-eye-mouth onset | Days 5 to 14 | Vesicles on skin, eye redness, or oral ulcers |
| CNS onset | Days 10 to 21 | Lethargy, seizures, poor feeding, or bulging fontanelle |
| Disseminated onset | Days 5 to 14 | Fever, liver dysfunction, respiratory distress, shock |
| Treatment course | 14 or 21 days | IV acyclovir for skin-eye-mouth or CNS/disseminated disease |
| Follow-up | Months to years | Hearing, vision, and developmental checks |
The incubation period is why a newborn can look well in the nursery and become ill at home. Skin-eye-mouth disease often appears first, but it can progress to CNS or disseminated disease if untreated. About 20% to 30% of neonatal HSV cases lack skin vesicles at presentation, so absence of a rash does not rule out infection. In plain terms: a normal newborn exam at discharge does not exclude HSV-1 exposure at delivery.
Treatment duration follows disease category. Skin-eye-mouth disease is usually treated for 14 days, while CNS and disseminated disease are treated for 21 days, per the 2021 AAP Red Book. The drug is given intravenously at 60 mg/kg per day divided every 8 hours. Earlier treatment improves outcomes, so the timeline is a clinical emergency clock, not a waiting schedule.
Neonatal HSV-1 Risks and Severe Outcomes
The question can you be born with HSV-1 often focuses on infection, but the bigger issue is severity. Population incidence is 1 in 2,500 to 1 in 10,000 live births, or roughly 0.01% to 0.04%. That is not the same as transmission risk after a known exposure. After a primary genital HSV infection at delivery, transmission risk is about 30% to 50%; after recurrent genital HSV, it is about 1% to 3%. These numbers are not contradictory because one describes the whole birth population and the other describes a high-risk exposure.
Untreated disseminated neonatal HSV has historically caused death in about 80% of cases. With IV acyclovir, mortality falls to about 30% for disseminated disease and about 4% to 15% for CNS disease. Skin-eye-mouth disease has low mortality with treatment, but it can recur or progress. Long-term neurologic impairment remains common after CNS disease, even when the infant survives. HSV-1 and HSV-2 cause the same syndromes, and HSV-1 now accounts for about 40% to 50% of neonatal HSV in many U.S. case series.
Seek emergency care for any infant under 6 weeks with these red flags:
- Fever of 38°C (100.4°F) or higher, or low temperature below 36.5°C (97.7°F)
- Vesicles anywhere, especially the scalp, face, eye, or mouth
- Poor feeding, lethargy, or unusual irritability
- Seizures, tremors, or a bulging fontanelle
- Breathing difficulty, jaundice, or signs of shock
- A maternal history of genital HSV near delivery, even without visible lesions
The most dangerous mistake is waiting for a classic cold sore. Neonatal HSV can begin as feeding difficulty or temperature instability. A clinician may need to perform HSV PCR from skin, blood, and cerebrospinal fluid, check liver enzymes, and start IV acyclovir before results return. The threshold for evaluation should be low when symptoms and maternal history fit.
Variations and Edge Cases
The route of acquisition changes the clinical picture. Intrauterine infection is rare and often apparent at birth. Perinatal infection is the dominant route and typically appears after discharge. Postnatal infection is uncommon but strongly linked to oral HSV-1 from a caregiver. The proportions below are approximate but useful for framing risk.
| Route | Share of neonatal HSV | Typical timing | Key mechanism |
|---|---|---|---|
| Intrauterine | About 5% | At birth or first 48 hours | Transplacental or ascending infection before labor |
| Perinatal | About 85% | Days 2 to 21 | Genital shedding during delivery |
| Postnatal | About 10% | After the first week | Oral secretions, hands, or breast lesions |
Preterm infants deserve special caution. They receive less maternal IgG, have thinner skin, and may have longer hospital stays with more handling. A preterm infant with HSV-1 can deteriorate faster than a term infant. Cesarean delivery lowers risk when done before membrane rupture, but it does not protect an infant already exposed through ascending infection. Asymptomatic shedding explains why a mother with no visible lesions can still transmit HSV-1.
HSV-1 versus HSV-2 matters less for acute treatment than for recurrence patterns. Genital HSV-1 recurs less often than genital HSV-2, so the risk of shedding at delivery may be lower in later pregnancies. However, primary HSV-1 near term is still a high-risk event. Postnatal HSV-1 from a cold sore is also a distinct edge case because the exposure happens after birth and is often preventable.
Misconceptions and Corrected Mechanisms
A common misconception is that HSV-1 only causes cold sores. HSV-1 can cause genital infection through oral-genital contact, and genital HSV-1 can be transmitted to a newborn during delivery. Another misconception is that “born with HSV-1” always means congenital infection. Most cases are acquired around birth and become symptomatic days later. True congenital HSV is the exception, not the rule.
Cesarean delivery is often treated as a guarantee. It reduces risk when performed before labor and membrane rupture, but it does not eliminate risk after prolonged rupture or ascending infection. Likewise, a lack of visible lesions does not mean a lack of shedding. Most genital HSV transmission occurs during unrecognized shedding, and neonatal exposure can happen without a maternal history of sores.
A cold sore in a caregiver is not a minor nuisance for a newborn. HSV-1 from oral secretions can cause skin-eye-mouth disease, CNS disease, or disseminated infection. The protective role of maternal antibody is also misunderstood. Antibody transfer is greatest in late pregnancy, so a primary infection near term is more dangerous than a recurrent infection in a mother who already has antibody.
What to Actually Do
Pregnant people with a history of genital HSV should tell their clinician early and again at delivery. For recurrent genital HSV, ACOG 2020 guidance supports antiviral suppression from 36 weeks to reduce recurrences and shedding. Valacyclovir 500 mg twice daily is a common regimen, but dosing should be individualized. If active genital lesions or prodromal symptoms are present at labor, cesarean delivery is usually recommended. Avoid oral-genital contact in late pregnancy when a partner has an active cold sore.
Caregivers should practice hand hygiene before holding a newborn. Do not kiss a newborn if you have an active cold sore, and cover lesions on the face or hands. Do not share utensils, towels, or pacifiers during an outbreak. If a breast lesion is present, avoid feeding from the affected breast and ask a clinician about pumping and discarding milk to maintain supply. These steps reduce postnatal HSV-1 exposure without isolating the family.
If an infant develops vesicles, fever, lethargy, poor feeding, or seizures, seek urgent pediatric care. Do not wait for the next office visit. Clinicians should start IV acyclovir promptly when neonatal HSV is suspected, even before PCR confirmation. Treatment is 14 days for skin-eye-mouth disease and 21 days for CNS or disseminated disease, per the 2021 AAP Red Book. Supportive care and developmental follow-up matter after discharge.
Limitations of the Evidence
Incidence estimates vary by region, case definition, and testing practice. Many mild skin-eye-mouth cases may be missed, while severe hospitalized cases are more completely counted. The HSV-1 share of neonatal HSV is changing as genital HSV-1 becomes more common, so older studies may not reflect current patterns. Attribution between HSV-1 and HSV-2 is further limited when typed PCR is not available.
Asymptomatic shedding limits prevention because clinicians cannot predict every exposure. Cesarean delivery reduces but does not erase risk. No licensed HSV vaccine exists, and antiviral suppression lowers recurrences without eliminating shedding. PCR can be negative early in infection, so a single negative test does not always exclude HSV. The answer to can you be born with HSV-1 is yes, but the probability and outcome depend heavily on timing, maternal immune status, and how quickly treatment begins.